DekaBank Deutsche Girozentrale’s Viking Therapeutics VKTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71M	Hold	57,330	–	–	﹤0.01%	718
2026 Q1	$1.74M	Hold	57,330	–	–	﹤0.01%	718
2025 Q4	$4.74M	Hold	57,330	–	–	0.01%	593
2025 Q3	$1.46M	Hold	57,330	–	–	﹤0.01%	807
2025 Q2	$1.5M	Buy	57,330 +45,330	+378%	+$1.19M	﹤0.01%	796
2025 Q1	$293K	Sell	12,000 -45,330	-79%	-$1.43M	﹤0.01%	1055
2024 Q4	$2.27M	Hold	57,330	–	–	﹤0.01%	718
2024 Q3	$3.57M	Hold	57,330	–	–	0.01%	651
2024 Q2	$3M	Buy	57,330 +45,330	+378%	+$2.97M	0.01%	679
2024 Q1	$1.01M	Buy	+12,000	New	+$534K	﹤0.01%	873

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DekaBank Deutsche Girozentrale's VKTX Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 57,330 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #718.

DekaBank Deutsche Girozentrale first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.74M in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

DekaBank Deutsche Girozentrale held 57,330 shares of Viking Therapeutics worth $1.71M as of Q2 2026.
DekaBank Deutsche Girozentrale left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #718 holding.
DekaBank Deutsche Girozentrale first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
DekaBank Deutsche Girozentrale's Viking Therapeutics position peaked at $4.74M in Q4 2025.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.